The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Yadernuk, Lisa M. - One of the best experts on this subject based on the ideXlab platform.
-
Temporohyoid osteoarthropathy and unilateral Facial Nerve Paralysis in a horse
Canadian Veterinary Medical Association, 2003Co-Authors: Yadernuk, Lisa M.Abstract:A 13-year-old broodmare was referred for weight loss and left Facial Nerve Paralysis. Bilateral temporohyoid osteoarthropathy was diagnosed based on proliferation of the temporohyoid joints and stylohyoid bones on radiographs and guttural pouch endoscopy. The left side was more severely affected. Treatment resulted in little or no improvement
Dale H Rice - One of the best experts on this subject based on the ideXlab platform.
-
idiopathic Facial Nerve Paralysis a randomized double blind controlled study of placebo versus prednisone
Laryngoscope, 1993Co-Authors: John R Austin, Steven P Peskind, Sara G Austin, Dale H RiceAbstract:Idiopathic Facial Nerve Paralysis (IFNP) is a common malady. Because its etiology is unclear, there are a variety of treatment options. Studies to date have not clearly established the benefits of treatment with oral steroids (prednisone). The authors performed a randomized double-blind controlled study comparing the use of placebo versus prednisone which shows that prednisone-treated patients benefit from early treatment. Seventy-six patients met inclusion criteria and completed follow-up until recovery; 35 patients received prednisone and 41 received placebo. Their mean age was 36.8 years. Facial Nerve function was assessed using the House-Brackmann Facial Nerve grading scale, as well as a variety of other measures
-
idiopathic Facial Nerve Paralysis a randomized double blind controlled study of placebo versus prednisone
Laryngoscope, 1993Co-Authors: John R Austin, Steven P Peskind, Sara G Austin, Dale H RiceAbstract:Idiopathic Facial Nerve Paralysis (IFNP) is a common malady. Because its etiology is unclear, there are a variety of treatment options. Studies to date have not clearly established the benefits of treatment with oral steroids (prednisone). The authors performed a randomized double-blind controlled study comparing the use of placebo versus prednisone which shows that prednisone-treated patients benefit from early treatment. Seventy-six patients met inclusion criteria and completed follow-up until recovery; 35 patients received prednisone and 41 received placebo. Their mean age was 36.8 years. Facial Nerve function was assessed using the House-Brackmann Facial Nerve grading scale, as well as a variety of other measures. Patients were evaluated pretreatment, regularly post-treatment until judged recovered (return of Facial function to a grade III or better), and at 6 months after recovery. Difference in mean time to resolution for the prednisone (51.4 days) and placebo (69.3 days) groups was not statistically significant. There was a significant difference in grade at recovery, with the placebo group having a higher proportion of grade III results (P < .03). Eight of 10 patients with electroneurography (ENOG) evidence of denervation were in the placebo group and accounted for 6 of the 7 grade III results. However, the difference in proportion of patients with evidence of denervation for the prednisone (5.7%) and placebo (19.5%) groups did not achieve statistical significance. This study shows that patients treated with prednisone have less denervation than placebo-treated patients. They also have a significant improvement in Facial grade at recovery compared to placebo-treated patients. Therefore, the authors recommend that all patients at risk for developing denervation receive prednisone treatment.
John R Austin - One of the best experts on this subject based on the ideXlab platform.
-
idiopathic Facial Nerve Paralysis a randomized double blind controlled study of placebo versus prednisone
Laryngoscope, 1993Co-Authors: John R Austin, Steven P Peskind, Sara G Austin, Dale H RiceAbstract:Idiopathic Facial Nerve Paralysis (IFNP) is a common malady. Because its etiology is unclear, there are a variety of treatment options. Studies to date have not clearly established the benefits of treatment with oral steroids (prednisone). The authors performed a randomized double-blind controlled study comparing the use of placebo versus prednisone which shows that prednisone-treated patients benefit from early treatment. Seventy-six patients met inclusion criteria and completed follow-up until recovery; 35 patients received prednisone and 41 received placebo. Their mean age was 36.8 years. Facial Nerve function was assessed using the House-Brackmann Facial Nerve grading scale, as well as a variety of other measures
-
idiopathic Facial Nerve Paralysis a randomized double blind controlled study of placebo versus prednisone
Laryngoscope, 1993Co-Authors: John R Austin, Steven P Peskind, Sara G Austin, Dale H RiceAbstract:Idiopathic Facial Nerve Paralysis (IFNP) is a common malady. Because its etiology is unclear, there are a variety of treatment options. Studies to date have not clearly established the benefits of treatment with oral steroids (prednisone). The authors performed a randomized double-blind controlled study comparing the use of placebo versus prednisone which shows that prednisone-treated patients benefit from early treatment. Seventy-six patients met inclusion criteria and completed follow-up until recovery; 35 patients received prednisone and 41 received placebo. Their mean age was 36.8 years. Facial Nerve function was assessed using the House-Brackmann Facial Nerve grading scale, as well as a variety of other measures. Patients were evaluated pretreatment, regularly post-treatment until judged recovered (return of Facial function to a grade III or better), and at 6 months after recovery. Difference in mean time to resolution for the prednisone (51.4 days) and placebo (69.3 days) groups was not statistically significant. There was a significant difference in grade at recovery, with the placebo group having a higher proportion of grade III results (P < .03). Eight of 10 patients with electroneurography (ENOG) evidence of denervation were in the placebo group and accounted for 6 of the 7 grade III results. However, the difference in proportion of patients with evidence of denervation for the prednisone (5.7%) and placebo (19.5%) groups did not achieve statistical significance. This study shows that patients treated with prednisone have less denervation than placebo-treated patients. They also have a significant improvement in Facial grade at recovery compared to placebo-treated patients. Therefore, the authors recommend that all patients at risk for developing denervation receive prednisone treatment.
Deborah Novicki - One of the best experts on this subject based on the ideXlab platform.
-
transient Facial Nerve Paralysis bell s palsy following intranasal delivery of a genetically detoxified mutant of escherichia coli heat labile toxin
PLOS ONE, 2009Co-Authors: David J M Lewis, Zhiming Huo, Susan W Barnett, Ingrid Kromann, Rafaela Giemza, Eva P Galiza, Maria Woodrow, Birgit Thierrycarstensen, Peter E Andersen, Deborah NovickiAbstract:An association was previously established between Facial Nerve Paralysis (Bell's palsy) and intranasal administration of an inactivated influenza virosome vaccine containing an enzymatically active Escherichia coli Heat Labile Toxin (LT) adjuvant. The individual component(s) responsible for Paralysis were not identified, and the vaccine was withdrawn.
-
transient Facial Nerve Paralysis bell s palsy following intranasal delivery of a genetically detoxified mutant of escherichia coli heat labile toxin
PLOS ONE, 2009Co-Authors: David J M Lewis, Zhiming Huo, Susan W Barnett, Ingrid Kromann, Rafaela Giemza, Eva P Galiza, Maria Woodrow, Birgit Thierrycarstensen, Peter E Andersen, Deborah NovickiAbstract:Background An association was previously established between Facial Nerve Paralysis (Bell's palsy) and intranasal administration of an inactivated influenza virosome vaccine containing an enzymatically active Escherichia coli Heat Labile Toxin (LT) adjuvant. The individual component(s) responsible for Paralysis were not identified, and the vaccine was withdrawn. Methodology/Principal Findings Subjects participating in two contemporaneous non-randomized Phase 1 clinical trials of nasal subunit vaccines against Human Immunodeficiency Virus and tuberculosis, both of which employed an enzymatically inactive non-toxic mutant LT adjuvant (LTK63), underwent active follow-up for adverse events using diary-cards and clinical examination. Two healthy subjects experienced transient peripheral Facial Nerve palsies 44 and 60 days after passive nasal instillation of LTK63, possibly a result of retrograde axonal transport after neuronal ganglioside binding or an inflammatory immune response, but without exaggerated immune responses to LTK63. Conclusions/Significance While the unique anatomical predisposition of the Facial Nerve to compression suggests nasal delivery of neuronal-binding LT–derived adjuvants is inadvisable, their continued investigation as topical or mucosal adjuvants and antigens appears warranted on the basis of longstanding safety via oral, percutaneous, and other mucosal routes.
Steven P Peskind - One of the best experts on this subject based on the ideXlab platform.
-
idiopathic Facial Nerve Paralysis a randomized double blind controlled study of placebo versus prednisone
Laryngoscope, 1993Co-Authors: John R Austin, Steven P Peskind, Sara G Austin, Dale H RiceAbstract:Idiopathic Facial Nerve Paralysis (IFNP) is a common malady. Because its etiology is unclear, there are a variety of treatment options. Studies to date have not clearly established the benefits of treatment with oral steroids (prednisone). The authors performed a randomized double-blind controlled study comparing the use of placebo versus prednisone which shows that prednisone-treated patients benefit from early treatment. Seventy-six patients met inclusion criteria and completed follow-up until recovery; 35 patients received prednisone and 41 received placebo. Their mean age was 36.8 years. Facial Nerve function was assessed using the House-Brackmann Facial Nerve grading scale, as well as a variety of other measures
-
idiopathic Facial Nerve Paralysis a randomized double blind controlled study of placebo versus prednisone
Laryngoscope, 1993Co-Authors: John R Austin, Steven P Peskind, Sara G Austin, Dale H RiceAbstract:Idiopathic Facial Nerve Paralysis (IFNP) is a common malady. Because its etiology is unclear, there are a variety of treatment options. Studies to date have not clearly established the benefits of treatment with oral steroids (prednisone). The authors performed a randomized double-blind controlled study comparing the use of placebo versus prednisone which shows that prednisone-treated patients benefit from early treatment. Seventy-six patients met inclusion criteria and completed follow-up until recovery; 35 patients received prednisone and 41 received placebo. Their mean age was 36.8 years. Facial Nerve function was assessed using the House-Brackmann Facial Nerve grading scale, as well as a variety of other measures. Patients were evaluated pretreatment, regularly post-treatment until judged recovered (return of Facial function to a grade III or better), and at 6 months after recovery. Difference in mean time to resolution for the prednisone (51.4 days) and placebo (69.3 days) groups was not statistically significant. There was a significant difference in grade at recovery, with the placebo group having a higher proportion of grade III results (P < .03). Eight of 10 patients with electroneurography (ENOG) evidence of denervation were in the placebo group and accounted for 6 of the 7 grade III results. However, the difference in proportion of patients with evidence of denervation for the prednisone (5.7%) and placebo (19.5%) groups did not achieve statistical significance. This study shows that patients treated with prednisone have less denervation than placebo-treated patients. They also have a significant improvement in Facial grade at recovery compared to placebo-treated patients. Therefore, the authors recommend that all patients at risk for developing denervation receive prednisone treatment.
